This course was last updated on
May 31, 2019
CME credit has expired.

In this activity, Alan Fleischer, Jr, MD, and Lindsay Strowd, MD, discuss the evolution in targeted treatments for atopic dermatitis based on improved understanding of pathophysiologic mechanisms. Supported by patient vignettes, they provide strategies for assessing the patient disease burden and its importance in developing an individualized treatment plan. Suggestions for greater patient engagement and improved self-management are also provided. The role and use of evidence-based nonpharmacologic and pharmacologic therapies are reviewed, focusing on dupilumab, for moderate-severe atopic dermatitis.

Content Areas

  • Pathophysiology
  • Epidemiology and risk factors
  • Clinical features
  • Basic management
  • Optimal use of topical therapies
  • Optimal use of systemic therapies
  • Dupilumab

Target Audience

This activity was developed for national audience (US) dermatologists, pediatric dermatologists, allergists, along with nurse practitioners and physician assistants within those specialties who manage patients with atopic dermatitis.


Alan B. Fleischer, Jr, MD
Alan B. Fleischer, Jr, MD
Professor and Residency Program Director
Department of Dermatology
University of Cincinnati College of Medicine
Cincinnati, Ohio
Lindsay C. Strowd, MD, FAAD
Lindsay C. Strowd, MD, FAAD
Assistant Professor of Dermatology
Wake Forest Baptist Health
Winston-Salem, North Carolina
Enter your information to begin.
CME Credit
Available Credit: 1.25 AMA PRA Category 1 Credits™.
1.25 AANP Contact Hours
1.25 ANCC Contact Hours
Opens: May 31, 2019
Expires: May 30, 2020
Target Audience: Allergists
Nurse Practitioners
Physician Assistants
Primary Care Physicians
Other Healthcare Providers
This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.